Sandoz Q2 Sales Beat Expectations as Biosimilars Surge 22%, Ushering in a 'Golden Decade'
核心洞察
Sandoz reported second-quarter net sales of $3.01 billion, a 9% increase year-over-year, narrowly surpassing the $2.99 billion analyst consensus.
Biosimilar net sales rose 22% at constant currencies, building on an 18% first-quarter jump, driven by patent expirations on reference biologics.
North American biosimilar sales surged 47% in the first half of 2026, fueled by launches of bone disease drug Wyost and osteoporosis (搜索) drug Jubbonti.
Swiss generic drug maker Sandoz reported a 9% increase in second-quarter net sales on Wednesday, reaching $3.01 billion and edging past the $2.99 billion consensus forecast compiled by Vara. The results underscore the company's accelerating push into biosimilars, a segment that management has characterized as entering its "golden decade."
Biosimilar net sales climbed 22% at constant currencies compared with the same quarter last year, following an 18% rise in the first quarter. The company had previously indicated that this upward trajectory should persist throughout the year. Sandoz is increasingly focusing on biosimilars — biological drugs based on reference medicines whose patents have expired and market exclusivity has been lost. These products are typically sold at significantly lower prices because they do not carry the burden of substantial research and development costs.
North America Leads Growth
The North American market proved particularly robust, with biosimilar sales growing 47% at constant currencies in the first half of the year. This performance was driven by the launches of Wyost, a bone disease drug, and Jubbonti, an osteoporosis (搜索) treatment. The strong regional showing reflects the broader industry dynamic in which innovator drugmakers — including Sandoz's former parent company Novartis — are confronting what they view as their most significant patent cliffs in decades. For Sandoz, however, these same patent expirations represent a generational opportunity.
GLP-1 Market Expansion
Sandoz is also positioning itself in the rapidly expanding GLP-1 market for diabetes (搜索) and obesity (搜索) drugs. Last week, the company received its first approval in Brazil for a multi-dose disposable pen formulation of semaglutide. In the United States, which represents the largest commercial opportunity in this space, the Food and Drug Administration agreed in June to review two generic tirzepatide GLP-1 products. If approved, these would compete directly with obesity drugs marketed by Eli Lilly. Despite these advances, Sandoz cautioned that it expects no material contribution from any potential generic semaglutide launch in 2026.
Pricing and Outlook
The company adjusted its pricing expectations, now forecasting a mid-single-digit percentage decline in 2026, compared with the previously anticipated low-to-mid single-digit percentage decline. This revision partly reflects short-term market dynamics in Germany and the strong biosimilar sales performance in North America. Sandoz confirmed its full-year guidance for both net sales and core EBITDA.